Compare Expeditors International of Wshngtn Inc (EXPD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Neurocrine Biosciences Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $24.81B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Expeditors International of Wshngtn Inc pays a 0.85% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EXPD | NBIX | |
|---|---|---|
Market Cap | $24.81B | $14.60B |
Volume | 832,787 | 1,075,694 |
Sector | Industrials | Health |
52-Week High | $194.12 | $185.50 |
52-Week Low | $113.13 | $123.10 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $24.34B | $14.61B |
Dividend Yield | 0.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.71, up 1.0% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 42.6% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts. Institutional activity shows mixed positioning with some major funds increasing stakes while others reduced exposure.
While EXPD shows strong operational metrics and earnings momentum, the stock trades above analyst consensus target of $174.86, suggesting limited near-term upside. Risks include competitive pressures and potential freight market volatility. The company's focus on efficiency and shareholder returns provides stability, but valuation remains elevated at 27.78 P/E ratio.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
